Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.345 HKD | -4.17% | +4.55% | -44.35% |
12/04 | Clover Biopharmaceuticals, Ltd. announced that it has received $0.320713 million in funding | CI |
08/04 | Clover Biopharmaceuticals' RSV Vaccine Candidate Shows Promise in Early Trial | MT |
Business Summary
Number of employees: 387
Managers
Managers | Title | Age | Since |
---|---|---|---|
Joshua Liang
CEO | Chief Executive Officer | - | 25/20/25 |
Aileen Wang
DFI | Director of Finance/CFO | - | 01/21/01 |
Htay Htay Han
CTO | Chief Tech/Sci/R&D Officer | 56 | 03/21/03 |
Wang Xiaoyan
SEC | Corporate Secretary | - | 31/23/31 |
Lily Yang
HRO | Human Resources Officer | - | 01/21/01 |
Liong Ho Chua
PRN | Corporate Officer/Principal | 60 | 27/22/27 |
Xiao Bing Li
PRN | Corporate Officer/Principal | 56 | 27/20/27 |
Hing Ling Chau
SEC | Corporate Secretary | 49 | 22/21/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jeffrey Farrow
BRD | Director/Board Member | 62 | 19/21/19 |
Xiao Dong Wang
BRD | Director/Board Member | 61 | 16/21/16 |
Xiao Bin Wu
BRD | Director/Board Member | 62 | 19/21/19 |
Donna Ambrosino
BRD | Director/Board Member | 72 | 17/22/17 |
Ralf Clemens
BRD | Director/Board Member | 71 | 17/22/17 |
Thomas Leggett
BRD | Director/Board Member | 47 | 19/21/19 |
Peng Liang
CHM | Chairman | 63 | 31/18/31 |
Joshua Liang
CEO | Chief Executive Officer | - | 25/20/25 |
Xiang Liao
BRD | Director/Board Member | 59 | 19/21/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,296,995,429 | 634,387,467 ( 48.91 %) | 0 | 48.91 % |
Company contact information
Clover Biopharmaceuticals Ltd.
49F, Park Place 1598-1601 West Nanjing Road
200010, Shanghai
+
http://www.cloverbiopharma.comSector
Sales per region
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-44.35% | 59.65M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+0.47% | 22.15B | |
-17.37% | 21.02B | |
-7.94% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- 2197 Stock
- Company Clover Biopharmaceuticals, Ltd.